Diadexus Inc (DDXS) 0.3530 $DDXS
Global Infectious Disease Molecular Diagnostics Market 2015: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Mon May 18, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3j3fm/2015_global) has announced the addition of the "2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new seven-country study contains 1,265 pages, 191 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/q3...015_global
MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81)
2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers
M2 - Mon May 18, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsnfz3/2015_analysis_of) has announced the addition of the "2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers" report to their offering. This 129-page report is designed to help suppliers identify and evaluate emerging opportunities for further automating molecular diagnostics methods in order to facilitate their penetration into the routine clinical laboratory market. Some instrumentation is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman Coulter, BD, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Gen-Probe, HTG Molecular, Life Technologies, Qiagen, Roche, Siemens and Tecan. The report also presents strategic assessments of current and emerging suppliers of molecular diagnostic products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Hologic/Gen-Probe - Illumina - Kreatech/Leica - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/fs...nalysis_of
SQNM: 3.74 (+0.05), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), HOLX: 34.62 (+0.18)
European Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6qmwp/2015_european) has announced the addition of the "2015 European Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 970-page comprehensive five-country report from a is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. France IV. Germany V. Italy VI. Spain VII. U.K. VIII. Major Product Development Opportunities IX. Design Criteria for Decentralized Testing Products X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments XIII. Appendix Companies Mentioned - Abbott - Affymetrix - Agilent - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Innogenetics/Solvay - Kreatech - Li-Cor Biosciences - Life Technologies - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Tecan Group For more information visit http://www.researchandmarkets.com/research/l6...5_european
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), CPHD: 58.56 (+0.85), NVS: 104.06 (+0.31)
United States Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jn7rn/2015_us_molecular) has announced the addition of the "2015 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 1157-page report from a contains 37 tables, and presents a comprehensive analysis of the US molecular diagnostics market, including: Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Review of testing methodologies an instrumentation technologies.Feature comparison of automated and semiautomated analyzers.Sales and market shares of leading suppliers.Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns. Five-year test volume and reagent sales forecasts for the following categories: - Infectious Diseases -Genetic Diseases - Cancer - Paternity Testing/HLA Typing - Forensic Testing Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Design Criteria for Decentralized Testing Products IV. Alternative Market Penetration Strategies V. Potential Market Entry Barriers and Risks VI. Worldwide Market and Technology Review VII. US Molecular Diagnostics Market VIII. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Exact Sciences - Fujirebio - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/7j..._molecular
MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81), HOLX: 34.62 (+0.18)
Diadexus, Inc. Reports First Quarter 2015 Financial Results
Marketwired - Tue May 12, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2015 and provided an update on the business.
Diadexus, Inc. to Report First Quarter 2015 Financial Results on May 12, 2015
Marketwired - Tue May 05, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report first quarter 2015 financial results on Tuesday, May 12, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus
Marketwired - Mon Apr 20, 8:30AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015.
Diadexus, Inc. Announces Presentation of Results From the PLAC(R) Activity Test Clinical Validation Study
Marketwired - Tue Mar 24, 1:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced results from the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) clinical validation study, presented for the first time today during an oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK. The results from this study were used in the 510(k) submission for this new test, which was cleared by the U.S. Food and Drug Administration in December 2014 for use in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events.
diaDexus misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:28PM CDT
Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 11, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and full year ended December 31, 2014.
Diadexus, Inc. Highlights Upcoming Oral Presentation of Data From the PLAC(R) Activity Test Validation Study at the EAS Meeting
Marketwired - Tue Mar 10, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that data validating the clinical performance of the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) has been accepted for oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK from March 21-25, 2015. This will be the first presentation of clinical validation data evaluated by the U.S. Food and Drug Administration that led to 510(k) clearance of the PLAC Activity Test in December 2014.
New finance chief at diaDexus
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 10:08AM CST
diaDexus, Inc. Announces Appointment of Leone Patterson as Chief Financial Officer
Marketwired - Mon Mar 02, 8:01AM CST
diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of Leone Patterson as chief financial officer.
Return To Growth Could Send Diadexus Shares Higher
Paul Nouri, CFP - Seeking Alpha - Thu Dec 25, 6:00AM CST
Diadexus (OTCQB: DDXS ) is a diagnostic company with a focus on cardiac diseases. Since going public in 2010, the company has grown sales from $12 million to $27 million in 2014. The company's primary test has been the FDA cleared PLAC ELISA test for...
FDA clears diaDexus CHD screening test
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 3:33PM CST
2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers
M2 - Mon Dec 08, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/vf9r39/20142018_us) has announced the addition of the "2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers" report to their offering. This unique report provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Biotest - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Grifols - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Takara Bio - Tecan Group For more information visit http://www.researchandmarkets.com/research/vf...0142018_us
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81)
2014-2018 US Nucleic Acid Testing/NAT Market: Sales and Market Shares of Major Suppliers
M2 - Mon Dec 08, 8:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/mz6ptk/20142018_us) has announced the addition of the "2014-2018 US Nucleic Acid Testing/NAT Market: Sales and Market Shares of Major Suppliers" report to their offering. This unique report provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Company Profiles - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Siemens - Sierra Molecular - Takara Bio - Tecan Group For more information visit http://www.researchandmarkets.com/research/mz...0142018_us
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81)
Major Molecular Diagnostic Product Suppliers by Country 2014: Sales and Market Shares Analysis
M2 - Mon Oct 06, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mbs9pk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Molecular Diagnostic Product Suppliers by Country" report to their offering. This unique report provides sales and market share estimates for major suppliers of molecular diagnostic products by country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Cepheid - Decode - Diadexus - Eiken - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/mb...and_market
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), CPHD: 58.56 (+0.85), HOLX: 34.62 (+0.18)
UK Major Molecular Diagnostic Product Suppliers Sales and Market Shares 2014
M2 - Mon Oct 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lgmvkt/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Molecular Diagnostic Product Suppliers" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/lg..._sales_and
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), HOLX: 34.62 (+0.18)
Italy Major Molecular Diagnostic Product Suppliers Sales and Market Shares 2014
M2 - Mon Oct 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zw7xts/italy_sales_and) has announced the addition of the "Italy Sales and Market Shares of Major Molecular Diagnostic Product Suppliers" report to their offering. This unique report provides Italy sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/zw..._sales_and
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), HOLX: 34.62 (+0.18)
Global Infectious Disease Molecular Diagnostics Market 2015: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Mon May 18, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3j3fm/2015_global) has announced the addition of the "2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new seven-country study contains 1,265 pages, 191 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/q3...015_global
MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81)
2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers
M2 - Mon May 18, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsnfz3/2015_analysis_of) has announced the addition of the "2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers" report to their offering. This 129-page report is designed to help suppliers identify and evaluate emerging opportunities for further automating molecular diagnostics methods in order to facilitate their penetration into the routine clinical laboratory market. Some instrumentation is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman Coulter, BD, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Gen-Probe, HTG Molecular, Life Technologies, Qiagen, Roche, Siemens and Tecan. The report also presents strategic assessments of current and emerging suppliers of molecular diagnostic products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Hologic/Gen-Probe - Illumina - Kreatech/Leica - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/fs...nalysis_of
SQNM: 3.74 (+0.05), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), HOLX: 34.62 (+0.18)
European Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6qmwp/2015_european) has announced the addition of the "2015 European Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 970-page comprehensive five-country report from a is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. France IV. Germany V. Italy VI. Spain VII. U.K. VIII. Major Product Development Opportunities IX. Design Criteria for Decentralized Testing Products X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments XIII. Appendix Companies Mentioned - Abbott - Affymetrix - Agilent - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Innogenetics/Solvay - Kreatech - Li-Cor Biosciences - Life Technologies - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Tecan Group For more information visit http://www.researchandmarkets.com/research/l6...5_european
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), CPHD: 58.56 (+0.85), NVS: 104.06 (+0.31)
United States Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jn7rn/2015_us_molecular) has announced the addition of the "2015 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 1157-page report from a contains 37 tables, and presents a comprehensive analysis of the US molecular diagnostics market, including: Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Review of testing methodologies an instrumentation technologies.Feature comparison of automated and semiautomated analyzers.Sales and market shares of leading suppliers.Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns. Five-year test volume and reagent sales forecasts for the following categories: - Infectious Diseases -Genetic Diseases - Cancer - Paternity Testing/HLA Typing - Forensic Testing Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Design Criteria for Decentralized Testing Products IV. Alternative Market Penetration Strategies V. Potential Market Entry Barriers and Risks VI. Worldwide Market and Technology Review VII. US Molecular Diagnostics Market VIII. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Exact Sciences - Fujirebio - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/7j..._molecular
MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81), HOLX: 34.62 (+0.18)
Diadexus, Inc. Reports First Quarter 2015 Financial Results
Marketwired - Tue May 12, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2015 and provided an update on the business.
Diadexus, Inc. to Report First Quarter 2015 Financial Results on May 12, 2015
Marketwired - Tue May 05, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report first quarter 2015 financial results on Tuesday, May 12, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus
Marketwired - Mon Apr 20, 8:30AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015.
Diadexus, Inc. Announces Presentation of Results From the PLAC(R) Activity Test Clinical Validation Study
Marketwired - Tue Mar 24, 1:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced results from the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) clinical validation study, presented for the first time today during an oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK. The results from this study were used in the 510(k) submission for this new test, which was cleared by the U.S. Food and Drug Administration in December 2014 for use in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events.
diaDexus misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:28PM CDT
Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 11, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and full year ended December 31, 2014.
Diadexus, Inc. Highlights Upcoming Oral Presentation of Data From the PLAC(R) Activity Test Validation Study at the EAS Meeting
Marketwired - Tue Mar 10, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that data validating the clinical performance of the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) has been accepted for oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK from March 21-25, 2015. This will be the first presentation of clinical validation data evaluated by the U.S. Food and Drug Administration that led to 510(k) clearance of the PLAC Activity Test in December 2014.
New finance chief at diaDexus
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 10:08AM CST
diaDexus, Inc. Announces Appointment of Leone Patterson as Chief Financial Officer
Marketwired - Mon Mar 02, 8:01AM CST
diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of Leone Patterson as chief financial officer.
Return To Growth Could Send Diadexus Shares Higher
Paul Nouri, CFP - Seeking Alpha - Thu Dec 25, 6:00AM CST
Diadexus (OTCQB: DDXS ) is a diagnostic company with a focus on cardiac diseases. Since going public in 2010, the company has grown sales from $12 million to $27 million in 2014. The company's primary test has been the FDA cleared PLAC ELISA test for...
FDA clears diaDexus CHD screening test
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 3:33PM CST
2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers
M2 - Mon Dec 08, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/vf9r39/20142018_us) has announced the addition of the "2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers" report to their offering. This unique report provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Biotest - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Grifols - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Takara Bio - Tecan Group For more information visit http://www.researchandmarkets.com/research/vf...0142018_us
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), CPHD: 58.56 (+0.85), DHR: 87.26 (+0.81)
2014-2018 US Nucleic Acid Testing/NAT Market: Sales and Market Shares of Major Suppliers
M2 - Mon Dec 08, 8:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/mz6ptk/20142018_us) has announced the addition of the "2014-2018 US Nucleic Acid Testing/NAT Market: Sales and Market Shares of Major Suppliers" report to their offering. This unique report provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Company Profiles - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Siemens - Sierra Molecular - Takara Bio - Tecan Group For more information visit http://www.researchandmarkets.com/research/mz...0142018_us
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81)
Major Molecular Diagnostic Product Suppliers by Country 2014: Sales and Market Shares Analysis
M2 - Mon Oct 06, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mbs9pk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Molecular Diagnostic Product Suppliers by Country" report to their offering. This unique report provides sales and market share estimates for major suppliers of molecular diagnostic products by country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Cepheid - Decode - Diadexus - Eiken - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/mb...and_market
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), CPHD: 58.56 (+0.85), HOLX: 34.62 (+0.18)
UK Major Molecular Diagnostic Product Suppliers Sales and Market Shares 2014
M2 - Mon Oct 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lgmvkt/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Molecular Diagnostic Product Suppliers" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/lg..._sales_and
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), HOLX: 34.62 (+0.18)
Italy Major Molecular Diagnostic Product Suppliers Sales and Market Shares 2014
M2 - Mon Oct 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zw7xts/italy_sales_and) has announced the addition of the "Italy Sales and Market Shares of Major Molecular Diagnostic Product Suppliers" report to their offering. This unique report provides Italy sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Fujirebio/Innogenetics - Grifols - Hologic/Gen-Probe - Illumina - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio For more information visit http://www.researchandmarkets.com/research/zw..._sales_and
LIFE: 19.90 (-0.23), MYGN: 34.25 (+0.27), A: 42.63 (+0.59), DHR: 87.26 (+0.81), SQNM: 3.74 (+0.05), HOLX: 34.62 (+0.18)
